GLP-1 Market Access | Policy & Market Intelligence

Description

List of Tables

Japan is the GLP-1 market that refuses to behave like the United States. Wegovy joined the NHI price list in February 2024, but under eligibility criteria tight enough to keep reimbursed obesity treatment a narrow channel; Mounjaro, launched in 2023, remains a diabetes-only brand; and Zepbound, approved in December 2024, is still working out how an obesity listing would be priced alongside its own twin. Around this regulated core, a parallel market grew fast: self-pay weight-loss clinics, telemedicine prescribers, and gray-market imports, until criminal referrals over illegal online sales in June 2026 signaled that enforcement had arrived. The tension in this market is not demand - Japan's obesity-related comorbidity burden and its clinic-dense primary-care system guarantee interest - but structure. How strict will NHI criteria remain as evidence accumulates in sleep apnea, MASH, and cardiovascular disease? How will regulators redraw the boundary between legitimate telemedicine and illegal online sales? What happens to lean-mass management when GLP-1 use spreads into an elderly, low-BMI population? And which of the challengers now in global development - oral small molecules, triple agonists, amylin combinations - will treat Japan as a launch market rather than an afterthought? This report maps the market as it actually operates: the reimbursement criteria and their practical effect, the self-pay and telemedicine channels and the enforcement framework now applied to them, supply and distribution mechanics, the indication-expansion sequence, and the competitive pipeline from orforglipron and MariTide to the China-origin assets moving through licensing deals. It then builds decision frameworks: what an obesity NHI filing requires, how challengers should time entry, and which policy events in 2026-2028 will reset the market. The report serves Lilly and Novo defending their franchises, challengers from Amgen, Roche, AstraZeneca, and the Chinese innovators weighing Japan, digital-health operators whose models depend on where the enforcement line settles, and investors who need to separate regulated-market facts from gray-market noise.

Scope and Coverage

The report covers NHI reimbursement rules and criteria for incretin therapies in Japan, self-pay and telemedicine channels and enforcement, supply and distribution, indication expansion, and the global pipeline with Japan relevance, with US, EU5, and China as reference markets.

Report Highlights

Wegovy NHI criteria in practice and the reimbursed-versus-self-pay channel split
The June 2026 criminal referrals and what they change for online weight-loss prescribing
Zepbound's access options in Japan, including the obstructive sleep apnea path
Pipeline mapping: orforglipron, MariTide, retatrutide, mazdutide, and China-origin oral assets
Lean-mass loss in Japan's elderly, low-BMI population and adjacent muscle-preservation programs
Entry-timing and evidence frameworks for challengers planning Japan filings

Product Code: JPH-097

Table of Content

1. Executive Summary

2. GLP-1 Market Access: Policy and Institutional Framework

3. Reimbursement, Pricing, and Funding Flows

4. Provider and Operator Landscape: Structure and Economics

5. Workforce and Capacity Analysis

6. Technology and Vendor Ecosystem

7. International Comparison: US, EU5, and China

8. Implications for Entrants and Investors

9. Appendix: Methodology and Sources

Companies Mentioned

Eli Lilly (US) - Mounjaro (T2D, launched 2023) and Zepbound (obesity, approved Dec 2024) in Japan; orforglipron oral follow-on
Novo Nordisk (DK) - Wegovy NHI-listed Feb 2024 under strict criteria; Ozempic/Rybelsus franchise; UBT251 in-licensed from United Laboratories
Amgen (US) - MariTide GIPR-antagonist/GLP-1 conjugate in the Phase 3 MARITIME program
Roche (CH) - CT-388 from the Carmot acquisition and the petrelintide amylin partnership with Zealand
Zealand Pharma (DK) - petrelintide originator partnered with Roche (2025)
Hengrui (CN) - HRS-9531 and oral GLP-1 assets out-licensed to Kailera
Kailera Therapeutics (US) - formed 2024 to develop Hengrui's GLP-1 portfolio outside Greater China
Innovent (CN) - mazdutide (GLP-1/glucagon, Lilly-originated) approved in China for weight management
AstraZeneca (UK) - ECC5004 oral small-molecule GLP-1 licensed from Eccogene (2023)
Eccogene (CN) - originator of ECC5004
United Laboratories (CN) - UBT251 GLP-1/GIP/glucagon triple agonist licensed to Novo Nordisk (2025)
Viking Therapeutics (US) - VK2735 injectable and oral dual-agonist programs
Structure Therapeutics (US) - aleniglipron (GSBR-1290) oral small-molecule GLP-1
Chugai (JP) - emugrobart muscle-preservation antibody relevant to GLP-1 lean-mass loss in Japan's low-BMI elderly

Product Code: JPH-097

List of Tables

Table 1. GLP-1 and incretin-class approvals in Japan by molecule, indication, and year
Table 2. NHI listing pathway for an obesity indication: the Wegovy listing (2024) as precedent
Table 3. Wegovy reimbursement criteria: eligibility thresholds, comorbidity requirements, and prescriber conditions
Table 4. Mounjaro in Japan: diabetes indication scope and the obesity-indication gap
Table 5. Zepbound Japan status: approval (2024) and the obstructive sleep apnea filing path
Table 6. Off-label and self-pay demand channels for GLP-1 agents in Japan
Table 7. Criminal referrals over illegal online GLP-1 sales (2026): channels, parties, and regulatory response
Table 8. MHLW telemedicine and online-prescribing rules as applied to weight-loss drugs
Table 9. Japan obesity-treatment guidelines and the place of pharmacotherapy
Table 10. Self-pay clinic models for medical weight management: service design and price structures
Table 11. Novo Nordisk Japan franchise: Wegovy, Ozempic, and Rybelsus lifecycle management
Table 12. Eli Lilly Japan franchise: Mounjaro launch (2023) and Zepbound follow-on strategy
Table 13. Orforglipron: oral small-molecule GLP-1 development and Japan program linkage
Table 14. Amgen MariTide: MARITIME Phase 3 program design and Japan relevance
Table 15. Roche incretin build-out: CT-388 via Carmot and the Zealand petrelintide partnership (2025)
Table 16. Retatrutide and triple-agonist programs relevant to Japan
Table 17. Innovent mazdutide: China weight-management approval and the Japan pathway question
Table 18. AstraZeneca ECC5004: the Eccogene license (2023) and oral GLP-1 development status
Table 19. Novo Nordisk UBT251: the United Laboratories license (2025) and triple-agonist positioning
Table 20. Viking VK2735 and Structure aleniglipron: Western challenger programs to watch
Table 21. Hengrui-Kailera licensing structure (2024) and the HRS-9531 program
Table 22. Amylin-pathway and combination approaches in Japan-relevant development
Table 23. GLP-1 supply-allocation history in Japan and availability by product
Table 24. Pharmacy distribution and cold-chain requirements for incretin presentations
Table 25. NHI price-formation treatment of dual T2D/obesity brands built on one molecule
Table 26. Prior-authorization and prescription-monitoring practices for reimbursed obesity treatment
Table 27. Employer and municipal health-program engagement with obesity pharmacotherapy
Table 28. Adherence and discontinuation patterns in Japanese real-world incretin use
Table 29. Lean-mass loss in elderly and low-BMI patients: monitoring protocols and co-interventions
Table 30. Chugai emugrobart and muscle-preservation programs adjacent to GLP-1 therapy
Table 31. Cardiovascular-outcome evidence shaping Japanese guideline positions
Table 32. Indication-expansion sequence in Japan: OSA, MASH, and CKD filings
Table 33. Japanese diabetes-treatment algorithms and incretin placement
Table 34. Specialist-versus-primary-care channel split for GLP-1 prescribing
Table 35. Digital-health weight-loss clinic models under regulatory scrutiny
Table 36. NHI pricing precedent for obesity indications: comparators and premium categories
Table 37. Cost-effectiveness arguments likely to shape future obesity-indication assessments
Table 38. Chuikyo discussions relevant to incretin-class spending
Table 39. Personal-import and gray-market channels: the enforcement framework
Table 40. Advertising and promotion rules applied to weight-loss medications in Japan
Table 41. Access scenarios for a Zepbound obesity listing in Japan: variables and decision points
Table 42. Scenario grid for oral GLP-1 entry and channel migration
Table 43. Competitive-position matrix across injectable and oral incretin programs
Table 44. Entry-timing questions for challengers evaluating Japan
Table 45. International obesity-access models and their lessons for Japan
Table 46. Risk register for manufacturers operating in Japan's GLP-1 market
Table 47. Risk register for digital-health channels in medical weight management
Table 48. Regulatory and reimbursement event watchlist for the incretin class in Japan, 2026-2028
Table 49. Stakeholder map: payers, regulators, societies, clinics, platforms, and manufacturers
Table 50. Timeline of GLP-1 market-access events in Japan, 2023-2026

List of Figures

Figure 1. Incretin-class product map in Japan by molecule and indication status
Figure 2. NHI listing decision pathway for a new obesity indication
Figure 3. Wegovy eligibility funnel under current reimbursement criteria
Figure 4. Reimbursed versus self-pay channel structure in medical weight management
Figure 5. Enforcement pathway for illegal online GLP-1 sales
Figure 6. Telemedicine prescribing rules as applied to weight-loss drugs
Figure 7. Novo Nordisk and Lilly Japan franchise architectures
Figure 8. Global incretin pipeline map by mechanism and development phase
Figure 9. Oral small-molecule GLP-1 programs and their Japan development linkage
Figure 10. Triple-agonist and amylin mechanisms entering clinical development
Figure 11. China-origin incretin assets and their licensing pathways toward Japan
Figure 12. Carmot and Zealand transactions in the Roche incretin build-out
Figure 13. Supply-allocation history and normalization for GLP-1 products in Japan
Figure 14. Cold-chain and distribution requirements across incretin presentations
Figure 15. Patient journey from obesity diagnosis to reimbursed pharmacotherapy
Figure 16. Self-pay clinic operating model for weight management
Figure 17. Adherence, discontinuation, and weight-regain dynamics observed in practice
Figure 18. Lean-mass monitoring concept for elderly GLP-1 users in Japan
Figure 19. Muscle-preservation pipeline adjacency to incretin therapy
Figure 20. Cardiovascular-outcome trial landscape shaping guideline updates
Figure 21. Indication-expansion sequence: T2D, obesity, OSA, MASH, and CKD
Figure 22. Japanese diabetes algorithm positioning of GLP-1 and GIP/GLP-1 agents
Figure 23. Obesity-society guidance and the specialist-versus-primary-care split
Figure 24. Digital weight-loss clinic models after the 2026 enforcement actions
Figure 25. NHI price-formation precedent for dual-brand single-molecule strategies
Figure 26. Cost-effectiveness framework relevant to obesity indications in Japan
Figure 27. Chuikyo policy discussion map for incretin-class spending
Figure 28. Personal-import and gray-market channel map
Figure 29. Advertising-rule boundaries for weight-loss promotion in Japan
Figure 30. Access-decision tree for Zepbound in Japan
Figure 31. Scenario tree for oral GLP-1 market formation
Figure 32. Competitive-position map of incretin programs with Japan relevance
Figure 33. Entry-timing framework for GLP-1 challengers in Japan
Figure 34. International obesity-access models benchmarked against Japan
Figure 35. Manufacturer risk map: supply, enforcement, pricing, and reputation
Figure 36. Digital-channel risk map: prescribing rules, advertising, and enforcement
Figure 37. Stakeholder influence map in Japanese obesity policy
Figure 38. Event calendar for the incretin class in Japan, 2026-2028
Figure 39. Demand-structure comparison: clinic-dense primary care versus specialist obesity care
Figure 40. Employer and municipal program pathways into obesity treatment
Figure 41. Real-world-evidence generation plan for reimbursed obesity therapy
Figure 42. Pharmacovigilance focus areas for the incretin class in Japan
Figure 43. Patent and exclusivity horizon for first-generation incretin products
Figure 44. Follow-on and biosimilar outlook for the GLP-1 class
Figure 45. Comorbidity-driven demand segmentation in the Japanese population
Figure 46. Channel-economics framework for obesity pharmacotherapy distribution
Figure 47. Investor question tree for the Japan GLP-1 theme
Figure 48. BD screening framework for in-licensing incretin assets into Japan
Figure 49. Market-access evidence checklist for an obesity NHI filing
Figure 50. Japan GLP-1 policy and market event timeline, 2023-2026

GLP-1 Market Access | Policy & Market Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. GLP-1 Market Access: Policy and Institutional Framework

3. Reimbursement, Pricing, and Funding Flows

4. Provider and Operator Landscape: Structure and Economics

5. Workforce and Capacity Analysis

6. Technology and Vendor Ecosystem

7. International Comparison: US, EU5, and China

8. Implications for Entrants and Investors

9. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures